Clin Mol Hepatol > Volume 26(3); 2020 > Article |
|
Study | Intervention | Trial details | Summary |
---|---|---|---|
Kirpich et al. [37] (2008) | Bifidobacterium bifidum and Lactobacillus plantarum 8PA3 vs. standard therapy | Randomized open-label trial | Reduced serum AST and ALT levels and increased relative abundance of Lactobacillus spp. and bifidobacteria in patients receiving probiotics |
Hospitalized male patients with alcoholic psychosis (n=66 total; n=26 had alcoholic hepatitis) | |||
Stadlbauer et al. [38] (2008) | Lactobacillus casei strain Shirota three times daily (every 8 hours) for 4 weeks | Open-label study | Neutrophilic phagocytic capacity improved relative to baseline |
Compensated alcoholic cirrhotics (n=10) | |||
Han et al. [39] (2015) | Bacillus subtilis and Enterococcus faecium vs. placebo for 7 days | Placebo-controlled trial | Improvements in liver function, systemic inflammation, and endotoxemia along with lower colony-forming unit count of Escherichia coli in the probiotic group |
Admitted patients with alcoholic hepatitis (n=117) | |||
Philips et al. [35] (2017) | FMT through nasoduodenal tube for 7 days | Open-label 1-year follow-up study | Improved survival and liver function in FMT group relative to among historical controls |
Steroid-ineligible male patients with severe alcoholic hepatitis (n=8) | Reduction in the potentially pathogenic species seen in the FMT group | ||
Philips et al. [40] (2018) | FMT daily for 7 days via nasoduodenal tube vs. corticosteroids, nutritional therapy, or pentoxifylline | Open-label study with 3-month follow-up | Three-month survival was highest in the FMT group |
Alcoholic hepatitis patients (all males) treated with FMT (n=16), pentoxifylline (n=10), corticosteroids (n=8), nutritional therapy (n=17) | Favorable gut microbial changes found in the FMT group | ||
Pande et al. (ongoing trial; NCT03091010) | FMT daily via nasoduodenal tube for 7 days vs. corticosteroids | Randomized controlled trial assessing 90-day survival between FMT and corticosteroids | Preliminary unpublished results showing 90-day survival benefits in the FMT group |
Saggere Muralikrishna Shasthry
https://orcid.org/0000-0002-5846-6263
Sinusoidal communication in chronic liver disease
Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease2024 January;30(1)
Implications of comorbidities in nonalcoholic fatty liver disease2023 April;29(2)
The growing burden of non-alcoholic fatty liver disease on mortality2023 April;29(2)